#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
This article examines the reliability and limitations of roadside THC testing devices used by law enforcement, alongside Saskatchewan Government Insurance’s zero-tolerance cannabis policy for drivers. Roadside saliva tests for THC have significant accuracy concerns, as they may not reliably correlate blood THC levels with actual impairment, unlike alcohol breath testing which has well-established impairment thresholds. The zero-tolerance approach creates legal and practical challenges for patients using cannabis therapeutically, as THC can remain detectable in saliva for extended periods even after impairment has resolved. For clinicians, this regulatory landscape is clinically relevant because patients prescribed cannabis for conditions like chronic pain or epilepsy may face legal consequences despite safe, responsible use and adequate time between dosing and driving. Patients should be counseled that current roadside testing technology does not account for individual tolerance, metabolism variation, or the distinction between acute intoxication and chronic cannabinoid presence in their system. Physicians should document therapeutic cannabis use in patient records and discuss the realistic legal risks patients face in their jurisdiction, as policy currently outpaces the science of impairment measurement.
“The problem with current roadside THC testing is that it measures presence, not impairment, which means we’re potentially penalizing patients using cannabis responsibly under medical supervision while missing genuinely impaired drivers. Until we develop reliable impairment markers rather than just THC detection, we need policy that distinguishes between the chronic patient with detectable metabolites and the person who smoked an hour ago.”
🚗 Roadside THC testing presents significant clinical and medicolegal challenges that warrant provider awareness, particularly given substantial variability in test accuracy, inability to correlate blood THC levels with impairment, and the persistence of THC in chronic users long after psychoactive effects have resolved. Current roadside screening tools lack the specificity of laboratory-based confirmatory testing, and unlike alcohol, no clear pharmacokinetic relationship exists between THC concentration and driving impairment across populations. Healthcare providers should recognize that patients may face serious legal consequences from zero-tolerance policies even when their cognitive function is unimpaired, while simultaneously understanding that some individuals genuinely experience cannabis-induced impairment that affects safety. When counseling patients on cannabis use, particularly those who drive or operate machinery, clinicians should emphasize that abstinence remains the only legally and pharmacologically certain approach to avoiding impairment-related risks, while acknowledging the gap between legal
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: